Orgenesis Completes Sale of Masthercell Subsidiary; Receives Approximately $127 Million in Net Proceeds
Orgenesis Inc. (ORGS)
NASDAQ:AMEX Investor Relations:
orgenesis.com
Company Research
Source: GlobeNewswire
Sale reflects culmination of successful CDMO strategy initiated in 2015 and 59% 5-year CAGR of Masthercell under Orgenesis’ leadership Reports rapid progress in roll-out of point-of-care (POCare) platform to capitalize on industry demand for patient cell processing and treatment within the patient care setting POCare platform poised for accelerated growth through industry partnerships underway with leading healthcare institutions around the world GERMANTOWN, Md., Feb. 11, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS), a provider of point-of-care cell and gene therapy development, processing and treatment solutions (“POCare”), today announced the completion of the sale of its Masthercell Global, Inc. subsidiary, a contract development manufacturing organization (CDMO), to Catalent Pharma Solutions. Upon closing, Orgenesis received net proceeds of approximately $127 million from the transaction. Orgenesis also provided an update and unveiled plans for its rapidly
Show less
Read more
Impact Snapshot
Event Time:
ORGS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ORGS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ORGS alerts
High impacting Orgenesis Inc. news events
Weekly update
A roundup of the hottest topics
ORGS
News
- Orgenesis Provides Third Quarter 2024 Business UpdateGlobeNewswire
- Orgenesis Commences Trading on OTCQX® Best MarketGlobeNewswire
- Orgenesis Announces Reverse Stock SplitGlobeNewswire
- Orgenesis Announces Positive Results From a Real-World Study of ORG-101 CAR-T Therapy in Patients with CD19+ Acute Lymphoblastic LeukemiaGlobeNewswire
ORGS
Sec Filings
- 11/13/24 - Form 10-Q
- 11/12/24 - Form 3
- 11/12/24 - Form 3
- ORGS's page on the SEC website